ONCOTELIC THERAPEUTCS INC (OTLC) earnings
OTLC earnings moved a median of +0.25% by the close. Quarterly and annual OTLC reports and results, each read against the price at its own news timestamp. Back to the OTLC overview →
19 measured OTLC earnings events.
Where these OTLC earnings landedvs 19 measured OTLC earnings reactions
| Middle 50% of OTLC earnings reactions | -3.00% to +3.81% |
|---|---|
| Median reaction (to close) | +0.25% |
| Measured reactions | 19 |
Point-in-time · zero look-ahead
Half of the 19 OTLC earnings events with a measured close landed between -3.00% and +3.81%; 58% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Oncotelic Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +0.25% | |
| Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress | Press release | -14.65% | -6.67% | |
| Form 10-Q Oncotelic Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -14.65% | -6.67% | |
| Form 10-K Oncotelic Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.12% | +5.49% | |
| Form NT 10-K Oncotelic Therapeutics, For: Dec 31 | SEC filing · Form NT | +0.00% | +0.32% | |
| Form 10-Q Oncotelic Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | — | +0.00% | |
| Form NT 10-Q Oncotelic Therapeutics, For: Sep 30 | SEC filing · Form NT | +0.00% | +11.12% | |
| Form 10-Q Oncotelic Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +0.00% | |
| Form 10-Q Oncotelic Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +15.04% | +1.76% | |
| Oncotelic Therapeutics Reports FY 2024 Highlights and FY 2024 Earnings Compared to FY 2023 | Press release | +0.00% | +3.60% | |
| Form 10-K Oncotelic Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.00% | +3.60% | |
| Form NT 10-K Oncotelic Therapeutics, For: Dec 31 | SEC filing · Form NT | — | +6.92% | |
| Form 10-Q Oncotelic Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -27.59% | |
| Form NT 10-Q Oncotelic Therapeutics, For: Sep 30 | SEC filing · Form NT | +0.00% | +4.01% | |
| Form 10-Q Oncotelic Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | — | -6.00% | |
| Form 10-Q Oncotelic Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +11.11% | +0.00% | |
| Form 10-K Oncotelic Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.00% | +0.24% | |
| Form NT 10-K Oncotelic Therapeutics, For: Dec 31 | SEC filing · Form NT | +0.00% | +4.72% | |
| Form 10-Q Oncotelic Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -23.26% |
Keep exploring
More OTLC: analyst actions → · SEC filings → · OTLC overview →